Recent studies indicate that ketamine exerts a suppressive effect on NF-κB signaling in depression and inflammation models, leading to a reduction in levels of stress mediators and pro-inflammatory factors [258]. This evidence concerns the gene NFKB1 and depressive symptom measurement.